Allergan Expands Leading Research & Development NASH Program with Novartis Clinical Collaboration

DUBLIN, April 18, 2017 /PRNewswire/ — Allergan, a leading global biopharmaceutical company, announced today that it has entered into a clinical trial agreement with Novartis to conduct a Phase 2b study, using Allergan’s cenicriviroc (CVC) and Novartis’ lead FXR agonist for the treatment o…–development-nash-program-with-novartis-clinical-collaboration-300440168.html

Filed under: Company